Nantong Acetic Acid Chemical Co Ltd

Nantong Acetic Acid Chemical Co Ltd has a debt-to-equity ratio of 0.44, indicating a relatively conservative capital structure. However, the company reported negative operating cash flow of -83.16 million CNY and negative operating income of -19.79 million CNY, signaling liquidity challenges. The current ratio of 1.79 suggests the company can cover its short-term liabilities with its short-term assets, but the negative net cash position after subtracting total debt raises concerns about its ability to meet long-term obligations.

Profitability metrics are weak, with a return on equity of -0.88% and a return on assets of -0.48%. These figures fall significantly below the industry median for Specialty Chemicals, which typically sees positive returns in both categories. The company's gross profit margin of 8.66% (67.38 million CNY on 778.03 million CNY revenue) is also below the median for its industry, indicating cost pressures or pricing challenges.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic downturns or supply chain disruptions. The absence of segment or geographic breakdown in the financials suggests a high concentration risk.

Looking ahead, the company is expected to face continued headwinds. Revenue is projected to decline in the current fiscal year, with no clear signs of recovery in the next fiscal year. The negative operating income and cash flow trends suggest a challenging growth trajectory, with no material capital expenditures or R&D investments to signal long-term value creation.

The risk assessment highlights liquidity as a medium concern, with the company's negative net cash position after subtracting total debt being a key flag. Dilution risk is currently low, as there is no indication of share issuance or dilution pressure in the near term. However, the company's negative operating performance and weak cash flow could lead to future financing needs, potentially increasing dilution risk.

Recent filings and transcripts do not provide additional insight into the company's strategic direction or operational performance. The lack of detailed disclosures in the latest financial statements and the absence of forward-looking guidance from management suggest limited transparency, which could affect investor confidence.

Free cash flow surged 103.9% year-over-year, indicating a significant improvement in the company's cash generation capabilities.

Operating income increased by 50.2% year-over-year, demonstrating strong operational leverage and improved core business profitability.

The company's debt-to-equity ratio of 0.44 is below the cohort median of 0.23, suggesting a conservative capital structure.

Cash conversion metrics rank as best-in-class compared to the specialty chemicals cohort, highlighting superior efficiency.

Net income grew 43.5% year-over-year, showing a recovery trajectory despite remaining negative in absolute terms.

The company faces high credit risk, which could impair its ability to secure favorable financing terms in the future.

Operating and net margins remain negative, placing the company in the bottom quartile of the specialty chemicals cohort.

Return on equity is negative at -0.88%, significantly underperforming the cohort median of 3.93%.

The company carries medium liquidity risk, potentially constraining its ability to meet short-term financial obligations.

Revenue ¥3.01B, −16,2% YoY; Operating income −92,6% YoY.

• ▍Revenue ¥3.01B, −16,2% YoY
• ▍Operating income −92,6% YoY
• ▍Net income −91,8% YoY
• ▍Free cash flow −140,5% YoY
• ▍Net margin 1.1%